We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > edaravone

News List

Post-Hoc Study Analysis Examines Early Intervention with Edaravone for ALS Survival americanpharmaceuticalreview
March 25, 2021
Mitsubishi Tanabe Pharma America announced a post-hoc analysis of its Phase 3 edaravone study reviewing the results of intravenous (IV) edaravone treatment on disease progression milestones and events among people with amyotrophic lateral sclerosis (ALS).
MTPA Announces Initiation of Open-Label Extension Study of Oral Edaravone in ALS americanpharmaceuticalreview
January 08, 2021
Mitsubishi Tanabe Pharma America (MTPA) announced the initiation of a long-term safety extension study (MT-1186-A03) to the ongoing Phase 3 trial evaluating an investigational oral formulation of edaravone in patients with amyotrophic lateral sclerosis.
Why Edaravone of Mitsubishi Tanabe is Excellent? PharmaSources/1℃
August 14, 2019
Edaravone of Mitsubishi Tanabe was approved for marketing in China on July 31, 2019, with the acceptance No.: JXHS1900047 and indication of amyotrophic lateral sclerosis (ALS).